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Abstract
Background: In this study, we examined the relative usefulness of serum copeptin levels as a surrogate marker of
vasopressin (AVP) in adult polycystic kidney disease (ADPKD) by correlating it with baseline and longitudinal changes in
markers of both renal function and common CVD manifestations (hypertensive vascular disease, atherosclerosis and
endothelial dysfunction) that accompany the progression of this disease.
Methods: We studied a cohort of young and otherwise healthy ADPKD patients (n = 235) and measured cardiovascular
function using flow-mediation dilatation (FMD), carotid intima media thickness (cIMT) and pulse wave velocity (PWV), as
well as serum copeptin (commercial ELISA, a stable marker of AVP activity). The same analyses were carried out at
baseline and after 3 years of follow-up.
Results: At baseline, median eGFR was 69 mL/min./1.73 m2, mean FMD 6.9 ± 0.9%, cIMT 0.7 ± 0.1 mm, and PWV 8.1 ± 1.
2 m/s. At follow-up, equivalent values were 65 (44–75) mL/min./1.73 m2, 5.8 ± 0.9%, 0.8 ± 0.1 mm. and 8.2 ± 1.3 m/s. with
all changes statistically significant. Plasma copeptin also rose from 0.62 ± 0.12 to 0.94 ± 0.19 ng/mL and this change
correlated with ΔeGFR (-0.33, p < 0.001), ΔFMD (0.599, p < 0.001), ΔcIMT (0.562, p < 0.001) and ΔPWV (0.27, p < 0.001) also
after linear regression modeling to correct for confounders. Finally, ROC analysis was done for a high baseline copeptin
with ΔeGFR [cut-off:≤59], ΔFMD [cut-off: ≤7.08], ΔcIMT [cut-off:>0.76], and ΔPWV [cut-off:≤7.80].
Conclusions: Vascular dysfunction as reflected by FMD and cIMT, but not PWV or an altered cardiac geometry, precede
most other signs of disease in ADPKD but is predicted by elevated levels of the circulating AVP-marker copeptin.
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is the most frequently hereditary cause of renal failure
but also an important cause of hypertension and cardio-
vascular diseases (CVD). Renal and extra-renal cystic
manifestations are the main characteristics of a disease
that often leads to the need for renal replacement ther-
apy by the sixth decade of life. The risk of CVD
morbidity and mortality are both highly elevated in
ADPKD as compared to the general population, but it is
not known if this is mainly a consequence of the disease
itself or if it is linked primarily to the drop in renal
function [1, 2].
Recent advances have linked cyst formation in
ADPKD to arginine-vasopressin hormone (AVP)-signal-
ling through the vasopressin V2-receptor and subse-
quent phosphodiesterase-driven cAMP modulation of
that signal [3, 4]. Clinically, the V2-antagonist tolvaptan
was recently shown to slow the increase in total kidney
volume and the decline in kidney function over a 3-year
trial period [5].
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Measuring AVP directly is difficult, as over 90% is
tightly bound to platelets [6]. Copeptin is a 39 amino
acid glycopeptides which forms the C-terminal part of
the AVP-precursor pre-provasopressin [7]. Activation of
the AVP-system drives copeptin secretion from the pos-
terior pituitary gland into the circulation in equimolar
amounts with AVP [8, 9]. Plasma copeptin is elevated in
patients with autosomal dominant polycystic kidney dis-
ease and predicts disease progression [10], but does not
appear to be heavily influenced by GFR [11].
In this study, we examined the relative usefulness of
serum copeptin levels as a surrogate marker of AVP by
correlating it with baseline and longitudinal changes in
markers of both renal function and common CVD man-
ifestations (hypertensive vascular disease, atherosclerosis
and endothelial dysfunction) that accompany the pro-
gression of ADPKD.
Methods
Patients, ethics, consent and permissions
Between March 2012 and March 2015, all 235 ADPKD
patients with normal renal function and followed at either
Kayseri Erciyes University School of Medicine or the
Ankara Gulhane School of Medicine (identified through
the Turkish Society of Nephrology’s Polycystic Kidney Dis-
ease Working Group Registry) were screened for inclusion
in the study. Prior approval for the study had been ob-
tained from the local ethics committees at both hospitals.
Eligible patients were invited to enroll in the study and,
following verbal and written information about the study,
asked to give written consent. Only patients that gave
written, informed consent to participate in the study were
recruited, and the study conformed to the Declaration of
Helsinki as amended. The study was prepared according
to the STROBE guidelines/methodology.
In enrolled patients, the diagnosis of ADPKD was re-
established based on clinical data, family history and a
new ultrasound of the kidneys using the criteria de-
scribed by Pei et al [12]. Demographic characteristics
(e.g. sex, age, education and smoking history), renal dis-
ease symptoms (e.g. history of hematuria, urinary tract
infections, kidney stone, etc.) and cardiovascular mani-
festations (e.g. hypertension and mitral valve prolapse)
were recorded using a web-based data collection form.
We excluded patients prescribed drugs likely to affect
copeptin (eg. loop diuretics (n = 7), SSRIs (n = 4),
NSAIDs (n = 6), demeclocycline (n = 1), statins (n = 10),
clofibrate (n = 2), chlorpromazine (n = 1), and vasopres-
sin analogues(n = 3). In the end, the study cohort com-
prised a total of 202 ADPKD patients with normal renal
function. At 36 months after the initial evaluation, pa-
tients were recalled and asked to undergo the same pro-
cedures a second time. Four patients did not complete
follow-up, but their data were kept for baseline analyses.
Ambulatory blood pressure
Blood pressure monitoring over 24 h was performed
using a Del Mar Medical Ressurometer Model P6 (Del
Mar Reynolds, Irvine, CA, USA) together with the man-
ufacturer’s software. Ambulatory measurements were
conducted once every 15min from 7 am until 11 pm,
and once every 30min from 11 pm until 7 am. Data were
summarized using the mean values for day and night.
Hypertension was considered to be present if the average
systolic pressure was ≥130 mmHg and/or the average
diastolic pressure was ≥80 mmHg for whole day, or if
the individual was taking any of the allowed antihyper-
tensive medications.
Biochemical analyses
Venous blood was drawn following a 12 h self-reported
fast in the morning due to circadian rhytmicity of AVP.
Glucose, creatinine, and lipids were assessed using
standard methods. Estimated GFR (eGFR) was calculated
using the Chronic Kidney Disease Epidemiology Collab-
oration (CKD-EPI) equation [13]. High sensitivity C-
reactive protein (hs-CRP) was measured using a BN2
model nephelometer (Dade-Behring, Germany). Copep-
tin was measured in serum using an ELISA kit from
Phoenix Pharmaceuticals (California, USA, cat. no. EK-
065-32). The reported intra- and inter-assay coefficients
of variation (CVs) reported by the manufacturer were
<10 and <15% respectively.
Echocardiography
All participants were examined using a Vivid 7 instru-
ment (GE Medical Systems, Milwaukee, WI, USA) with
a 2.5-MHz transducer and harmonic imaging. The echo-
cardiographies were all performed by a specialist in
echocardiography and according to the recommenda-
tions of the American Society of Echocardiography.
Briefly, at least three consecutive beats in sinus rhythm
were recorded, and the average values used. The LV
end-diastolic and end-systolic dimensions (LVEDD and
LVESD) and interventricular septal and posterior wall
thicknesses (IVSd and LPWd) were measured from M-
mode images of the left ventricle generated in the long-
axis view with the cursor at the tip of the mitral valve
leaflets. The LV ejection fraction was calculated using
the formula: LVEF % = (LVEDV − LVESV)/LVEDV × 100.
The left ventricular mass (LVM) was calculated using
the formula: LVM = 0.8 × (1.04 [(IVSd + LVEDD +
LPWd) 3 − (LVEDD) 3)) + 0.6 g [14].
Endothelial function test
Endothelial dysfunction was assessed according to the
transient ischemia method described by Celemajer et al.
[15]. Measurements were made by a single observer
using an ATL 5000 ultrasound system (Advanced
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Technology Laboratories Inc., Bothell, WA, USA) using
a 12-Mhz probe. Three adjacent measurements of end-
diastolic brachial artery diameter were made from single
2D frames. The maximum flow-mediated vasodilation
(FMD) diameter was calculated by averaging three con-
secutive measurements, and FMD was then calculated as
the percentage change in diameter compared with base-
line. All images were recorded for subsequent blinded
analysis.
Thickness of the carotid artery intima-media (c-IMT)
Ultrasonographic studies on common carotid artery was
done on both sides and using high-resolution Doppler
ultrasound (ATL 5000) with a 5–12 MHz linear trans-
ducer. A single blinded operator performed all measur-
ents on two stored longitudinal images of each artery.
The four values were averaged to calculate mean c-IMT.
Pulse wave velocity
Pulse wave analysis was performed twice on each side, in
the carotid and femoral arteries. We used a machine
(Micro Medical Pulse Trace, Rochester, UK) in accord-
ance with the manufacturer’s recommendations. PWV
was calculated automatically by measuring the time for
the pulse wave to travel between the carotid and femoral
arteries. All measurements were performed over 15
heart beats by a single operator.
Statistical analysis
Shapiro-Wilk’s test, histogram and q-q plots were exam-
ined to assess normal distribution. Levene test was per-
formed to assess the variance in homogenity. The
statistical significance of differences between groups
were assessed by two-way paired t- test (normally dis-
tributed data) or Wilcoxon t- test (non-normal distribu-
tion). In multivariate analyses, all variables for which a
unadjusted, univariate linear regression analysis showed
a p-value <0.10 were included in a backward elimination
multivariate linear regression analysis, with the
remaining variables compared as concerns risks by using
the likelihood ratio tests. p < 0.05 was considered signifi-
cant, and the confidence interval (CI) was set to 95%.
All statistical analyses were performed using SPSS ver-
sion 15 (SPSS,Inc., Chicago, Ill., USA).
Results
Patient characteristics at baseline and follow-up
Demographical features of the 202 ADPKD patients
are summarized in Table 1. Baseline biochemical,
echocardiographic and other recorded data along with
those obtained after 3 years are given in Table 2. As
expected, there was a small but statistically significant
decrease in eGFR (69[54–78] to 65[44–75] mL/min/
1.73 m2; p < 0.001) and hemoglobin during follow-up,
while serum phosphorus, HDL- and LDL- cholesterol,
plasma glucose, average 24-h systolic and diastolic
blood pressure (SBP and DBP), and proteinuria all
rose. Of the studied markers of cardiovascular func-
tion, LVM (1.1%; p < 0.001), PWV (2%; p < 0.001),
cIMT (14%; p < 0.001), copeptin (52%; p < 0.001) and
hs-CRP (165%; p < 0.001) all increased during follow-
up, while FMD (-16%; p < 0.001) decreased (Table 2,
Fig. 1). There were no statistically significant changes
in LVM, LVEF or LVED.
Univariate correlations and regression
At baseline, Spearman Rank analysis showed significant
correlations between serum copeptin and proteinuria
(rho = 0.35; p < 0.01), mean 24 h systolic (rho = 0.17;
p < 0.05) and diastolic (rho = 0.22; p < 0.01) blood pres-
sures, cIMT (rho = 0.63; p < 0.001), eGFR (rho = -0.30,
p < 0.001) and urine osmolality (rho = 0.43; p < 0.001).
We next performed univariate regression analysis to
assess correlations between changes in copeptin over
time with Δ PWV (r2 = 0.03; p < 0.05), Δ cIMT (r2 = 0.32;
p < 0.01) and Δ FMD (r2 = 0.39; p < 0.001) (Tables 3 and 4
and Fig. 2).
Multivariate modelling
We explored the observed associations using multiple
regression analyses including baseline factors associated
with copeptin at p < 0.10 in univariate analyses (PWV,
FMD, LVM, Proteinuria, U-osmolarity, U-volume, cIMT,
LVEDD) (Table 3). We also performed regression ana-
lyses of changes over time (Table 4). Of the variables
associated with change in eGFR (total model coefficient;
p < 0.01), SBP (coefficient -0.35; p < 0.001) and copeptin
(-0.33; p < 0.001) emerged as independent. Similar values
were obtained for predictors of PWV and FMD, which
was also predicted by changes in blood cholesterol and
triglycerides. Regarding cIMT, DBP, proteinuria, copep-
tin and CRP emerged were found as independent predic-
tors (total model coefficient; p < 0.001). Also, DBP,
proteinuria, CRP and cIMT variables were found to be
Table 1 Baseline clinical characteristic of the 202 ADPKD
patients
Variable n(%)





Receiving oral hypoglycemictherapy 10(5)
With cardiovascular comorbidities 7(3)
Values are expressed as mean ± standard deviation or frequency (percentage)
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the most essential variables in predicting Δ copeptin
(total model coefficient; p < 0.001, Table 4).
Baseline copeptin as a predictor of future changes
We optimized the positive predictive value of copep-
tin by performing separate ROC-analyses for each of
the CVD surrogates (Table 5). Using these cut-offs,
we next applied separate Logistic Regression Models
to assess the predictive value of a plasma copeptin
above or below these cut-offs for the change (Δ) in
the outcome variable until follow-up (Table 5). Fi-
nally, multivariate modeling using only baseline pa-
rameters was performed to assess the independence
of copeptin as a predictor of future changes in CVD
markers (Table 6).
Discussion
In this study we measured common surrogate markers
of hypertensive (PWV and LVM), atherosclerotic (cIMT)
and endothelial (warm ischemia induced FMD) CVD in
early-stage ADPKD. All analyses were repeated after a
mean 36 months, and we related the results both to each
other and to serum levels of the marker of AVP-activity,
copeptin. Our data demonstrates that signs of cardiovas-
cular dysfunction, especially of the endothelium, develop
already in ADPKD patients with preserved renal func-
tion and progresses at a more rapid rate than that of the
decline in renal function (assessed as eGFR). We also
found that serum levels of copeptin are elevated already
before a decline in eGFR in these patients, and that the
degree of elevation correlates with functional markers of
CVD and also predict a future decline in GFR as well as
in FMD.
The most important finding of the present study is the
characterization of the vascular dysfunction that appears
at an early stage of ADPKD and that may be related to
the hypertension commonly seen in these patients.
Based on our findings, vascular dysfunction in ADPKD
Table 2 Comparison of clinical, echocardiographic features and biochemical data before and after 3 year follow-up
Variable Reference values Baseline (n = 202) Follow-up (n = 202) ΔChange% p
eGFR(ml/min/1.73 m2) >90 69.0(54.0–78.0) 65.0(44.0–75.0) −5.80 <0.001
BMI (kg/m2) 20–24 24.67 ± 2.78 24.98 ± 2.47 1.26 0.212
Calcium (mg/dl) 8.8–10.2 8.27 ± 0.45 8.19 ± 0.31 −0.97 0.039
Sodium (mmol/L) (135–144) 139.48 ± 4.22 137.59 ± 3.62 −1.37 0.066
Phosphorus (mg/dl) 2.5–4.5 4.80(4.13–5.30) 5.70(4.80–8.20) 18.75 <0.001
HDL Cholesterol (mg/dl) 45–65 43(39.0–46.0) 45.0(40.25–47.00) 4.65 0.003
LDL Cholesterol (mg/dl) 100–130 123(118–129) 128(109–139) 4.07 0.005
Total Cholesterol (mg/dl) 70–200 193.71 ± 15.02 194.05 ± 16.44 0.18 0.843
Triglyceride (mg/dl) 40–130 140.37 ± 11.41 134.46 ± 11.19 −4.21 <0.001
Hemoglobin (g/l) 12–16 14.0(12.8–14.7) 13.6(13.1–14.0) −2.86 0.002
Glucose (mg/dl) 82–115 85.0(78–120) 88(80–115) 3.53 0.001
Urine volume (mL) - 1868 ± 572 1780 ± 568 −3.71 <0.001
U-osmolarity (mOsm/kg) - 205(178–245) 289(254–395) 42.85 <0.001
Average 24-h systolic BP, mmHg <130 135 ± 6.9 142 ± 7.2 5.19 <0.001
Average 24-h diastolic BP, mmHg <80 83 ± 4.8 86 ± 5.3 3.61 <0.001
Proteinuria (mg/day) 0–150 1100 (500–1870) 1540 (720–2600) 40.00 <0.001
Left ventricular ejection fraction(%) >55 64.4 ± 5.0 62.1 ± 5.8 −3.57 0.245
Left ventricular mass (g) 49–115 169.4 ± 37.3 171.3 ± 46.5 1.12 0.311
Left ventricular end-diastolic diameter (mm) 42–59 46.5 ± 2.9 47.0 ± 3.4 0.88 0.175
PWV (m/sec) - 8.10 ± 1.20 8.24 ± 1.34 1.73 0.044
FMD, % - 6.92 ± 0.87 5.78 ± 0.92 −16.47 <0.001
CIMT(mm) - 0.72 ± 0.11 0.82 ± 0.08 13.89 <0.001
Copeptin (ng/mL) N/A 0.62 ± 0.12 0.94 ± 0.19 51.61 <0.001
Hs-CRP (mg/l) <0.2 3.40(2.20–4.0) 9.00(5.10–19.0) 164.71 <0.001
Values are expressed as mean ± standard deviation or median(1st–3rdquartiles)
p value below 0.05 was considered significant and significant parameters were shown by bold type
ΔChange (%) : (follow up value- baseline value)/baseline value*100
eGFR, estimated glomerular filtration rate, BMI Body massindex, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, Hs-CRP High
sensitivity C-reactive protein, PWV Pulse wave velocity, c-IMT carotid artery intima-media thickness
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Fig. 1 Comparison of arterial function markers and circulating copeptin values at baseline and after 36 months in 202 ADPKD patients. PWV,
pulse-wave velocity. CIMT, carotid artery intima media thickness. FMD, post-ischemia flow mediated vasodilation





















S-Copeptin (ng/mL) 1.000 - - - - - - - - -
Proteinuria (mg/day) 0.346** 1.000 - - - - - - - -
SBP (mmHg) 0.171* 0.095 1.000 - - - - - - -
DBP (mmHg) 0.216** 0.257** 0.273** 1.000 - - - - - -
U-osmolarity (mOsm/kg) 0.430** 0.132 0.097 0.070 1.000 - - - - -
U-volume (mL) −0.030 −0.036 −0.102 −0.187** 0.001 1.000 - - - -
cIMT (mm) 0.643** 0.268** 0.088 0.274** 0.236** −0.028 1.000 - - -
LVM (g) 0.118 0.055 0.158 0.089 0.085 0.099 0.128 1.000 −0.145 -
LVEDD (mm) −0.069 0.142 0.094 0.166 0.022 0.128 0.056 0.133 1.000 -
eGFR (ml/min/1.73 m2) −0.304** −0.386** −0.253** −0.272** −0.204** 0.063 −0.355** −0.162 0.137 1.000
*p < 0.05
**p < 0.01
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Table 4 Univariate and multivariate models analysing the correlations between changes (Δ) in PWV, eGFR, copeptin, cIMT and FMD in ADPKD patients
Variable ΔPWV ΔFMD ΔeGFR Δcopeptin ΔcIMT
Univariate Multiple Univariate Multiple Univariate Multiple Univariate Multiple Univariate Multiple
ΔBMI (kg/m2) 0.056(0.429) - −0.053(0.457) - 0.083(0.243) - 0.019(0.685) - 0.133(0.054) -
ΔCalcium (mg/dl) 0.206(0.003) - 0.011(0.881) - −0.038(0.595) - 0.134(0.200) - 0.063(0.420) -
ΔPhosphorus (mg/dl) 0.113(0.112) - 0.027(0.708) - 0.117(0.100) - 0.109(0.150) - 0.055(0.460) -
ΔHDL Cholesterol (mg/dl) 0.117(0.099) - −0.149(0.035) −0.175(0.002) 0.071(0.319) - 0.085(0.365) - −0.048(0.484) -
ΔLDL Cholesterol (mg/dl) 0.260(<0.001) - −0.037(0.604) - −0.016(0.827) - 0.053(0.460) - −0.038(0.594) -
ΔTotal Cholesterol (mg/dl) −0.111(0.118) - −0.143(0.044) - 0.056(0.432) - 0.091(0.332) −0.056(0.360) -
ΔTriglyceride (mg/dl) 0.170(0.016) - 0.194(0.006) 0.146 (0.010) −0.101(0.154) - −0.107(0.102) - 0.099(0.163) -
Δ Hemoglobin (g/l) −0.008(0.910) - −0.030(0.675) - 0.081(0.256) - 0.080 (0.134) - 0.079(0.283) -
ΔGlucose (mg/dl) 0.060(0.398) - −0.075(0.293) - −0.127(0.073) - −0.050 (0.705) - 0.117(0.110) -
ΔAverage 24-h SBP, mmHg 0.128(0.026) 0.249(0.001) 0.366(0.005) 0.268(0.017) −0.429(<0.001) −0.348(<0.001) 0.383(<0.001) - 0.317(<0.001) -
ΔAverage 24-h D BP, mmHg −0.018(0.799) - −0.180(0.011) - 0.079(0.263) - 0.493(<0.001) 0.313(<0.001) 0.385(<0.001) 0.142(0.030)
ΔProteinuria (mg/day) 0.045(0.523) - −0.170(0.016) - 0.060(0.400) - 0.168(0.018) 0.133(0.018) 0.168(0.017) 0.131(0.028)
Δ CIMT(mm) 0.138(0.051) - −0.302(<0.001) - −0.065(0.364) - 0.562(<0.001) 0.347(<0.001) - -
Δ Copeptin (ng/mL) 0.179(0.011) 0.267(<0.001) 0.599(<0.001) 0.582(<0.001) −0.414(<0.001) −0.331(<0.001) - - 0.562(<0.001) 0.391(<0.001)
ΔHs-CRP (mg/l) 0.120(0.034) - 0.255(<0.001) - −0.182(0.009) - 0.378(<0.001) 0.196(0.001) 0.372(<0.001) 0.210(0.001)












is related to endothelial function (FMD) and potentially
atherosclerosis (cIMT) more than to fluid overload
(PWV) or cardiac failure (echocardiography). We
[16, 17] and others [18, 19] have previously reported
an impaired vascular function during early-stage
ADPKD in cross-sectional studies and single mo-
dalities assessing vascular functions, while Peterson
et al. [20] studied endothelium-dependent vasodila-
tion in a rat model of ADPKD and reported changes
there that preceded a rise in mean arterial pressure
or drop in GFR. With the present data, these find-
ings are extended and broadened, demonstrating the
consistent nature of ADPKD vasculopathy (early on-
set, FMD worse than cIMT, which in turn is worse
than PWV and precedes any changes in cardiac
geometry) as well as the extent to which vascular
decline precedes that of GFR and also develops at a
faster rate.
Regarding potential mechanisms mediating the ob-
served endothelial dysfunction, Peterson et al. [20]
found that administration of L-arginine (a precursor
of nitric oxide, NO) was able to restore vascular func-
tion in their model, suggesting a key role for NO sig-
naling. Consistent with this finding, Lothioir et al.
[21] recently reported that FMD induced by warm-
ischemia, but not that induced by NO, is impaired in
ADPKD. Studying 21 normotensive patients (eGFR
99 ± 18 mL/min/1.73 m2, 36% smokers) they found a
maintained ability to dilate vessels following infusion
of an NO-donor, while warm ischemia led to a mark-
edly blunted response in patients as compared to
controls. Furthermore, infusion of dopamine was able
to ameliorate also the warm-ischemia induced FMD
in these patients, further strengthening the reported
link between ADPKD and impaired dopaminergic sig-
naling reported previously [22, 23]. Barendregt and
colleagues [22] studied eight hypertensive ADPKD pa-
tients and reported that urinary dopamine excretion
is increased at all levels of sodium intake, while
stimulation of renal dopamine production was able to
normalize renal hemodynamics, making dopamine re-
ceptor agonism a potential therapeutic option. Mean-
while Abdul-Majeed and Nauli [23] used transgenic
mice to demonstrate an important role for dopamine
receptor (DR)5 in regulating endothelial ciliary length
and function in close cooperation with PKD1. Indeed
the DR5-linked chemo-sensory function of endothelial
cell cilia could even alter the sensitivity to fluid-shear
Fig. 2 Univariate correlations between serum copeptin with PWV, CIMT and FMD in 202 young ADPKD patients with well-preserved
renal function
Table 5 Statistical usefullness of serum copeptin levels as a marker of a FMD, PWV, eGFR, or CIMT above or below the variable
median for the cohort at baseline
Variable Area under curve Diagnostic statistics
AUC p Co-peptin cut-off
used (from ROC)
SEN (%) SPE (%) PPV(%) NPV(%)
FMD (> or ≤7.1%) 0.75(0.68–0.80) <0.001 0.59 ng/mL 88.0(79.6–93.6) 57.4(47.5–66.9) 63.8(54.8–72.1) 84.9(74.6–92.2)
PWV (> or ≤7.8 m/sec) 0.58(0.50–0.65) 0.064 0.76 ng/mL 51.1(40.4–61.7) 71.3(61.8–79.6) 60.8(48.5–71.2) 63.1(53.9–71.7)
eGFR(> or ≤59 mL/min/1.73 m2) 0.61(0.54–0.68) 0.008 0.81 ng/mL 43.5(33.2–55.2) 60.2(50.3–60.9) 52.2(41.4–62.9) 59.1(49.3–68.4)
cIMT (> or ≤0.8 mm) 0.86(0.80–0.90) <0.001 0.58 ng/mL 79.4(69.6–87.1) 88.9(81.4–94.1) 85.9(76.6–92.5) 83.5(75.4–89.7)
AUC Area under curve, SEN Specificity, SPE Specificity, PPV Positive predictive value, NPV Negative predictive value
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Table 6 Multivariate modeling to assess the independence of plasma copeptin as a marker of changes in cardiovascular function and eGFR
Variables ΔFMD ΔPWV ΔeGFR ΔcIMT
Univariate OR(95%CI) Adjusted OR(95%CI) Univariate OR(95%CI) Adjusted OR(95%CI) Univariate OR(95%CI) Adjusted OR(95%CI) Univariate OR(95%CI) Adjusted OR(95%CI)
ΔLDL (mg/dl) −0.109(0.125) - −0.179(0.011) −0.162(0.018) 0.007(0.925) - 0.072(0.311) -
ΔAverage 24-h SBP,
(mmHg)
−0.167(0.018) - 0.015(0.828) - 0.112(0.115) - 0.017(0.810) -
ΔAverage 24-h
D BP,(mmHg)
−0.061(0.394) - 0.007(0.917) - 0.104(0.142) - 0.055(0.442) -
ΔFMD (%) - - −0.163(0.021) - 0.029(0.688) - −0.197(0.005) -
ΔPWV (m/sec) −0.106(0.135) - - - 0.041(0.565) - −0.177(0.012) −0.162(0.009)
ΔeGFR(ml/min/
1.73 m2)
−0.223(0.001) −0.252(<0.001) −0.265(<0.001) −0.253(<0.001) - - −0.448(<0.001) −0.473(<0.001)
ΔcIMT (mm) −0.334(<0.001) - −0.024(0.737) - −0.188(0.008) −0.188(0.008) - -
ΔCopeptin (ng/mL) −0.431(<0.001) −0.448(<0.001) 0.014(0.839) - −0.109(0.125) - −0.238(0.001) −0.240(<0.001)












stress, providing a mechanistic explanation for the
previous observations.
In the present study, hypertension and alterations in
vascular functions were predicted by an elevated baseline
circulating copeptin, while changes in copeptin closely
followed those in SBP, FMD, cIMT, and, to a lesser ex-
tent, PWV. This is consistent with the hypothesis that
copeptin functions as a more stable marker of AVP re-
lease in response to changes in plasma osmolality and
other factors. Recently, the role of AVP in ADPKD has
received much attention. Studies have linked AVP-
signalling through V2 receptors in the distal renal tu-
bules and collecting ducts to a rise in intracellular
cAMP-levels [24] that in turn stimulates cyst growth by
several mechanisms that may include chloride-driven
fluid secretion from proliferating cyst-derived cells [25].
Meijer et al. [26] demonstrated a relationship between
serum copeptin levels and total renal volume, albumin-
uria, renal blood flow and eGFR. Bortien et al. [10] fur-
ther established an association between a baseline
elevation in copeptin levels and a future decrease in
GFR; however, this relation was not found to be inde-
pendent from other risk factors.
The present study confirms and expands the previ-
ous literature by establishing a strong and independent
longitudinal 3-year association both between copeptin
and eGFR changes, as well as link an elevated copeptin
to impaired ischemia-mediated FMD. This may offer
observational support for the hypothesis that dopamin-
ergic inhibition of AVP-driven AQP2 expression and
recruitment to the cell membrane [27] reflects a more
general modulating role on AVP-signalling and en-
courages the investigation of dopamine a potential
therapeutic in ADPKD. Indeed, in the 3-years random-
ized clinical TEMPO 3:4 trial [5], the V2-inhibitor tol-
vaptan was shown to retard cyst growth and GFR
decline in ADPKD-patients, but the price of the drug
has been criticized as high [28] while the number of
patients that discontinued treatment due to adverse re-
actions was significantly higher with tolvaptan than
with placebo.
A number of limitations of the study design should
be acknowledged and kept inmind when interpreting
the results. First, we did not perform genetic profil-
ing of the included ADPKD patients and thus have
no way of telling whether PKD1, PKD2 or even
undescribed mutations caused the phenotype. Sec-
ondly, we did not measure kidney volumes in the
study subjects either at baseline or follow-up. We
are thus unable to relate copeptin levels to radio-
logical signs of disease progression. Finally, this is a
cohort study without active interventions, precluding
the attribution of causality to the predictive statis-
tical relationships.
Conclusion
Vascular dysfunction as reflected by FMD and cIMT, but
not PWV or an altered cardiac geometry, precede most
other signs of disease in ADPKD but is predicted by
elevated levels of the circulating AVP-marker copeptin.
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